APA (7th ed.) Citation

Satwani, P., Dela Cruz, F., Le Gall, J., Jin, Z., Bhatia, M., Garvin, J., . . . Cairo, M. (2011). A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and alloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY). Biology of Blood & Marrow Transplantation, 17(2), S247. https://doi.org/10.1016/j.bbmt.2010.12.283

Chicago Style (17th ed.) Citation

Satwani, P., et al. "A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and AlloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY)." Biology of Blood & Marrow Transplantation 17, no. 2 (2011): S247. https://doi.org/10.1016/j.bbmt.2010.12.283.

MLA (9th ed.) Citation

Satwani, P., et al. "A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and AlloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY)." Biology of Blood & Marrow Transplantation, vol. 17, no. 2, 2011, p. S247, https://doi.org/10.1016/j.bbmt.2010.12.283.